The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksETX.L Share News (ETX)

  • There is currently no data for ETX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Daily Mail General Trust's Chairman sells £15.91m-worth of shares

Fri, 04th Jul 2014 16:30

Viscount Rothermere, the Chairman of Daily Mail and General Trust, has traded in £15.91m-worth of shares in the multi-media and information company. Selling the stock at 860p a piece, Rothermere benefited from the rise seen in the group's share price this week, which has seen it climbed 5.56%, or 45.5p. He disposed of a total of 1.85m shares, leaving him with 64.33m, equivalent to 18.23% of the issued share capital. Top Director BuysSTM Group (STM) Director name: Mr Alan Roy KentishAmount purchased: 1,666,667 @ 18.00p Value: £300,000Frontier Developments (FDEV) Director name: Mr David Ranken GammonAmount purchased: 20,000 @ 230.00p Value: £46,000STM Group (STM) Director name: Mr Therese NeishAmount purchased: 250,000 @ 18.00p Value: £45,000Accesso Technology Group (ACSO) Director name: Mr David Ranken GammonAmount purchased: 7,500 @ 510.00p Value: £38,250STM Group (STM) Director name: Mr Colin PorterAmount purchased: 200,000 @ 18.00p Value: £36,000Frontier Developments (FDEV) Director name: Mr David John Braben Amount purchased: 15,000 @ 230.00p Value: £34,500Mercantile Investment Trust (The) (MRC) Director name: Mr Harry MorleyAmount purchased: 2,000 @ 1,485.20p Value: £29,704e-Therapeutics (ETX) Director name: Mr Steve MedlicottAmount purchased: 100,000 @ 29.00p Value: £29,000STM Group (STM) Director name: Mr Julian TellingAmount purchased: 138,889 @ 18.00p Value: £25,000Harvey Nash Group (HVN) Director name: Mr Albert EllisAmount purchased: 17,294 @ 110.00p Value: £19,023Top Director SellsDaily Mail and General Trust A (Non.V) (DMGT) Director name: The Viscount RothermereAmount sold: 1,850,000 @ 860.00p Value: £15,910,000Hargreaves Lansdown (HL.) Director name: Ms Tracey TaylorAmount sold: 70,682 @ 1,272.00p Value: £899,075Hargreaves Lansdown (HL.) Director name: Ms Tracey TaylorAmount sold: 32,687 @ 1,275.00p Value: £416,759Hargreaves Lansdown (HL.) Director name: Mr Dharmash MistryAmount sold: 5,308 @ 1,267.00p Value: £67,252NR
More News
20 Mar 2018 16:14

UK Earnings, Trading Statements Calendar - Next 7 Days

Wednesday 21 March KingfisherFull Year ResultsAlpha FXFull Year In SportFull 22

Read more
9 Jan 2017 08:49

E-Therapeutics Hires Amgen Director As New Chief Executive

Read more
6 Oct 2016 11:23

DIRECTOR DEALINGS: e-Therapeutics Non-Executive Acquires Shares

Read more
14 Sep 2016 11:23

e-Therapeutics Development Director Steve Self To Step Down

Read more
13 Jul 2016 09:13

E-Therapeutics Chairman Takes On Executive Duties As CEO Steps Down

Read more
1 Jun 2016 08:03

e-Therapeutics Offer For Searchbolt Now Wholly Unconditional

Read more
25 May 2016 08:18

e-Therapeutics Focused On Validation Of Drug Discovery Platform

Read more
18 May 2016 15:05

AGM, EGM Calendar - Week Ahead

Read more
12 May 2016 11:13

DIRECTOR DEALINGS: E-Therapeutics Non-Executive Acquires Shares

Read more
11 May 2016 09:06

e-Therapeutics To Buy Searchbolt For GBP2.3 Million (ALLISS)

Read more
22 Mar 2016 11:40

E-Therapeutics Loss Widens As Active Projects Increase

Read more
15 Mar 2016 16:15

Earnings, Trading Statements Calendar - Week Ahead

Read more
15 Feb 2016 10:43

WINNERS & LOSERS SUMMARY: Reckitt Benckiser Results Please Investors

Read more
15 Feb 2016 09:45

E-Therapeutics depression drug trials miss targets

(ShareCast News) - Drug trials results for e-Therapeutics' depression treatment were not as successful as had been hoped, sending shares in the company sharply lower. Phase IIb clinical trials of the company's ETS6103 product did not achieve the aim of matching the efficacy of existing tricyclic ant

Read more
15 Feb 2016 08:20

E-Therapeutics Shares Drop As ETS6103 Trials Miss Primary Endpoint

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.